These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
3. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP; N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794 [TBL] [Abstract][Full Text] [Related]
4. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374 [TBL] [Abstract][Full Text] [Related]
7. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398 [TBL] [Abstract][Full Text] [Related]
8. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic. Pogge EK; Davis LE Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335 [TBL] [Abstract][Full Text] [Related]
9. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956 [TBL] [Abstract][Full Text] [Related]
10. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ; Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854 [TBL] [Abstract][Full Text] [Related]
11. ▼ Sacubitril valsartan for heart failure. Drug Ther Bull; 2016 Jun; 54(6):66-9. PubMed ID: 27284124 [TBL] [Abstract][Full Text] [Related]
12. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Jhund PS; McMurray JJ Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980 [TBL] [Abstract][Full Text] [Related]
13. The safety of sacubitril-valsartan for the treatment of chronic heart failure. Tyler JM; Teerlink JR Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547 [TBL] [Abstract][Full Text] [Related]
14. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure. Rodgers JE Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069 [TBL] [Abstract][Full Text] [Related]
15. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Kario K Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807 [TBL] [Abstract][Full Text] [Related]
16. Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial. Shaddy R; Burch M; Kantor PF; Solar-Yohay S; Garito T; Zhang S; Kocun M; Bonnet D Circ Heart Fail; 2023 Mar; 16(3):e009816. PubMed ID: 36601956 [TBL] [Abstract][Full Text] [Related]
17. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. Ansara AJ; Kolanczyk DM; Koehler JM J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects. Krittanawong C; Kitai T Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28489317 [TBL] [Abstract][Full Text] [Related]
19. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction. McCormack PL Drugs; 2016 Mar; 76(3):387-96. PubMed ID: 26873495 [TBL] [Abstract][Full Text] [Related]
20. Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: A pharmacovigilance study. Guion-Firmin J; Tessier S; Lepelley M; Faillie JL; Montastruc JL Fundam Clin Pharmacol; 2022 Apr; 36(2):378-389. PubMed ID: 34260768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]